Retinal Degenerative Diseases XIX
Home > Medicine & Health Science textbooks > Clinical and internal medicine > Ophthalmology > Retinal Degenerative Diseases XIX: Mechanisms and Experimental Therapy(1415 Advances in Experimental Medicine and Biology)
Retinal Degenerative Diseases XIX: Mechanisms and Experimental Therapy(1415 Advances in Experimental Medicine and Biology)

Retinal Degenerative Diseases XIX: Mechanisms and Experimental Therapy(1415 Advances in Experimental Medicine and Biology)


     0     
5
4
3
2
1



International Edition


X
About the Book

This book contains the proceedings of the XVIII International Symposium on Retinal Degeneration (RD2018). A majority of those who spoke  and presented posters at the meeting contributed to this volume. The blinding diseases of inherited retinal degenerations have no treatments, and age-related macular degeneration has no cures, despite the fact that it is an epidemic among the elderly, with 1 in 3-4 affected by the age of 70. The RD Symposium focused on the exciting new developments aimed at understanding these diseases and providing therapies for them. Since most major scientists in the field of retinal degenerations attend the biennial RD Symposia, they are known by most as the “best” and “most important” meetings in the field. The volume presents representative state-of-the-art research in almost all areas of retinal degenerations, ranging from cytopathologic, physiologic, diagnostic and clinical aspects; animal models; mechanisms of cell death; candidate genes, cloning, mapping and other aspects of molecular genetics; and developing potential therapeutic measures such as gene therapy and neuroprotective agents for potential pharmaceutical therapy. While advances in these areas of retinal degenerations were described, there will be many new topics that either are in their infancy or did not exist at the time of the last RD Symposium. These include the role of inflammation and immunity, as well as other basic mechanisms, in age-related macular degeneration, several new aspects of gene therapy, and revolutionary new imaging and functional testing that will have a huge impact on the diagnosis and following the course of retinal degenerations, as well as to provide new quantitative endpoints for clinical trials. The retina is an approachable part of the central nervous system (CNS), and there is a major interest in neuroprotective and gene therapy for CNS diseases and neurodegenerations, in general. It should be noted that withsuccessful and exciting initial clinical trials in neuroprotective and gene therapy, including the restoration of sight in blind children, the retinal degeneration therapies are leading the way towards new therapeutic measures for neurodegenerations of the CNS. Many of the successes recently reported in these areas of retinal degeneration sprang from collaborations established at previous RD Symposia, and many of those were reported at the RD2016 meeting and included in the current volume. We anticipate the excitement of those working in the field and those afflicted with retinal degenerations is reflected in the volume. 

Table of Contents:
High Resolution Imaging Mass Spectrometry of Human Donor Eye: Photoreceptor Cells and Basal Laminar Deposits of Age-related Macular Degeneration.- The non-canonical role of Complement Factor H in Retinal Pigment Epithelium (RPE) cells and implications for Age-related Macular Degeneration.- Macular Pigment Carotenoids and Bisretinoid A2E.- Disturbed matrix metalloproteinases activity in age-related macular degeneraton.- Current views on Chr10q26 contribuiton to age-related macular degeneration.- Untargeted lipidomic profiling of aged human retina with and without age-related macular degeneration (AMD).- Decoding Race and Age-Relation Macular Degeneration: GPR 143 Activity is the Key.- Peroxisome proliferator-activated receptor gamma coactivator 1 alpha ( PGC-1x): a transcriptional regulator at the interface of aging and age-related macular degeneration?.- Regulation of ABCA1 by miR-33 and miR-34a in the aging eye.- The role of gene expressionregulation on genetic risk of Age-related Macular Degeneration.- Elastin layer in Bruch's membrane as a target for immunizatio or tolerization to modulate patthology in the mouse model of somke-induced ocular injury.- Repuprosing drugs for treatment of age-relation macular degeneration.- Extracellular Vesicle RNA Contents as Biomarkers for Ocular Diseases.- Proteomics of retinal extracellular vesicles: a reviw inot an unexplored mechanism in retinal health and AMD pathogenesis.- Prime Editing Strategy to Instally the PRHP2 c.828+1G A mutations.- Analysis of CRB1 Pathogenic Variants Correctable with CRISPR Base and Prime Editing.- Generation of an Avian Myeloblastosis Virus (AMV) Reverse Transcriptase Prime Editor.- Pre-existing neutralizing antibodies against different adeno-associated virus serotypes in humans and large animal models for gene therapy.- Optimization of Capillary-based Western Blotting for MYO7A.- AAV Serotypes and Their Suitability for RetinalGene Therapy.- Gene Augmentation ofautosomal dominant CRX-associated retinopathies.- Txnip gene therapy of retinitis pigmentosa improves cone health Factors affecting readthrough of natural versus premature termination codons.- Integrating Computational Approaches to Predict the Effect of Genetic Variants on Protein Stability in Retinal Degenerative Disease.- Network biology and medcine to resuce: Applications for retinal disease mechanisms and therapy.- Non-sydromic Retinal Degeneration Caused by Pathogenic Variants in Joubert Syndrome Genes.- Exonic variants that affect splicing- an opportunity for "hidden" mutations causing inherited retinal diseases.- Enhanced S-cone Syndrome, a Mini-Review.- The role of microglia in Inherited Retinal Diseases.- CD68: potential contributor to inflammation and RPE cell dystrophy.- Gene Expression of Clusterin, Tissue Inhibitor of Metalloproteinase-1, and Their receptors in Retinal Pigment Epithelial Cells and Muller Glial Cells is Modulated by Inflammatory Stresses.- Axonal Transport Defects in Retinal Ganglion Cells.- Connexins biology in the pathophysiology of retinal diseases.- Role of Nuclear NAD +in Retinal Homeostasis.- Retinal pigmented epithelium-derived ectopic norrin does not promote intraretinal angiogenesis in transgenic mice.- Caveolin-1 Muller glia exist as heat-resistant,high molecular weight complexes.- Role of VLC-PUFAs in Retinal and Macular Degeneration.- Ocular amyloid , condensates, and aggregates - higher order protein assemblies participate in both retinal degeneration and function.- Photoreceptor ion channels in signaling and disease.- The role of peripherin-2 /ROM1 complexes in photoreceptor outer segment disc morphogenesis.- Human mutations in Arl3, a small GTPase involved inlipidated cargo delibery to the cilia cause retinatl dystropthy.- Genotype-Phenotype Association in ABCA4-Associated Retinopathy.- Retinal pathoconnectomics: A Window into Neurodegeneration.- The role of Ceramide in Inherited Retinal Disease Pathology.- Extracelluar Matix: the Unexplored Aspects of Retinal Pathologies and Regeneration.- Role of TFEB in diseases assocaited with lysosomal dysfunction.- Retinoic acid receptor -related oprhan receptors (RORs) in eye development and disease.- A novel mouse model for Late-Onset Retinal Degeneration (L-ORD) devekios RPE abnormalities due to the loss of C1qtnf5/Ctrp5.- Comparison of mouse models of autosomal dominant retinitis pigmentosa due to P23H muations of Rhodopsin.- Compensatory Cone-Mediated Mechanisms in Inherited Retinal Degeneration Mouse Models: A Functional and Gene Expression Analsyis.- Inhibition of Ryanodine Receptor 1 Reduces Endoplasmic Reticulum (ER) Sress and Promotes ER Protein Degradation in Cyclic Nucleotide-gated Channel Deficiency.- Mouse choroid proteome revisited: foucs on aging.- Morphological and functional comparison of mice models for retinitis pigmentosa.- Current Advancements in Mouse Models of Retinal Disease.- Single-cell ItrnacriptomicProfiling of Muller Glia in the rd10 Retina.- Methods for in vivo characterization of proteostatis in the mouse retina.- Absence or PRCD leads to dysregulation in lipie Homeostatis resulting in disorganizationof photorecptor outer segment structure.- Expansion Microscopy of Mouse Photoreceptro Cilia.- Rod photorecptor specific ablation of Metformin target, AMPK, in preclinical model of autosomal recessvie retinitis pigmentosa.- TLR2 is highly overexpressed in retinal myeloid cells in the rd10 mouse model of retinitis pigmentosa.- Environmental light has an essentail effrect on the diseasae expression in a dominant RPE65 mutation.- Microglia Preserve Visual Function in A Mouse Model of Retinitis Pigmentosa with Rhodopsin-P23H Mutant.- Measuring the release of lactate from wild-type and rd1 mouse retina.- Aerobic glycolysis in photorecptors supports energy demand in the absence of mitochondrial coupling.- Redox Status in Retinitis Pigmentosa.- Perspectives on retinal dolichol metabolismand visual deficits in dolichol metalbolism-associated inherited disorders.- Retinal metabolic profile on IMPG2 deficiency mice with subretinal lesions.- Glutathione-coating of liposomes enhances the delivery of hydrophillic cargo to the inner nuclear layer in retinal cultures.- Modification of Mueller glial cell fate and proliferation with the use of small molecules.- A potential neuroprotective role for pyruvate kinase 2 in retinal degeneration.- Critical role of VEGF as a direct regulator of photorecptor function.- Lysine Ubiquitylation Drives Rhodopsin Protein Turnover.- In-silico prediction of MYO!C Rhodopsin Interactions and its Significance in Protein Localization and Visual Function.- A ciliary branched actin netowrk drives photoreceptor disc morphogenesis.- Revisiting the daily timing of POS phagocytosis.- Inhibition of Bacterial Peoptidoglycan Cytopahty by Retina Pigment Epithelial PGRP2 Amidase.- Understanding ischemic retinopathies: the role of Succinate and its recpto^T mutation.- Inducing neural regeneratio nfrom glia using proneural bHLH transcription factors.


Best Sellers


Product Details
  • ISBN-13: 9783031276804
  • Publisher: Springer International Publishing AG
  • Publisher Imprint: Springer International Publishing AG
  • Height: 254 mm
  • No of Pages: 588
  • Returnable: Y
  • Sub Title: Mechanisms and Experimental Therapy
  • ISBN-10: 3031276809
  • Publisher Date: 14 Jul 2023
  • Binding: Hardback
  • Language: English
  • Returnable: Y
  • Series Title: 1415 Advances in Experimental Medicine and Biology
  • Width: 178 mm


Similar Products

Add Photo
Add Photo

Customer Reviews

REVIEWS      0     
Click Here To Be The First to Review this Product
Retinal Degenerative Diseases XIX: Mechanisms and Experimental Therapy(1415 Advances in Experimental Medicine and Biology)
Springer International Publishing AG -
Retinal Degenerative Diseases XIX: Mechanisms and Experimental Therapy(1415 Advances in Experimental Medicine and Biology)
Writing guidlines
We want to publish your review, so please:
  • keep your review on the product. Review's that defame author's character will be rejected.
  • Keep your review focused on the product.
  • Avoid writing about customer service. contact us instead if you have issue requiring immediate attention.
  • Refrain from mentioning competitors or the specific price you paid for the product.
  • Do not include any personally identifiable information, such as full names.

Retinal Degenerative Diseases XIX: Mechanisms and Experimental Therapy(1415 Advances in Experimental Medicine and Biology)

Required fields are marked with *

Review Title*
Review
    Add Photo Add up to 6 photos
    Would you recommend this product to a friend?
    Tag this Book Read more
    Does your review contain spoilers?
    What type of reader best describes you?
    I agree to the terms & conditions
    You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.

    CUSTOMER RATINGS AND REVIEWS AND QUESTIONS AND ANSWERS TERMS OF USE

    These Terms of Use govern your conduct associated with the Customer Ratings and Reviews and/or Questions and Answers service offered by Bookswagon (the "CRR Service").


    By submitting any content to Bookswagon, you guarantee that:
    • You are the sole author and owner of the intellectual property rights in the content;
    • All "moral rights" that you may have in such content have been voluntarily waived by you;
    • All content that you post is accurate;
    • You are at least 13 years old;
    • Use of the content you supply does not violate these Terms of Use and will not cause injury to any person or entity.
    You further agree that you may not submit any content:
    • That is known by you to be false, inaccurate or misleading;
    • That infringes any third party's copyright, patent, trademark, trade secret or other proprietary rights or rights of publicity or privacy;
    • That violates any law, statute, ordinance or regulation (including, but not limited to, those governing, consumer protection, unfair competition, anti-discrimination or false advertising);
    • That is, or may reasonably be considered to be, defamatory, libelous, hateful, racially or religiously biased or offensive, unlawfully threatening or unlawfully harassing to any individual, partnership or corporation;
    • For which you were compensated or granted any consideration by any unapproved third party;
    • That includes any information that references other websites, addresses, email addresses, contact information or phone numbers;
    • That contains any computer viruses, worms or other potentially damaging computer programs or files.
    You agree to indemnify and hold Bookswagon (and its officers, directors, agents, subsidiaries, joint ventures, employees and third-party service providers, including but not limited to Bazaarvoice, Inc.), harmless from all claims, demands, and damages (actual and consequential) of every kind and nature, known and unknown including reasonable attorneys' fees, arising out of a breach of your representations and warranties set forth above, or your violation of any law or the rights of a third party.


    For any content that you submit, you grant Bookswagon a perpetual, irrevocable, royalty-free, transferable right and license to use, copy, modify, delete in its entirety, adapt, publish, translate, create derivative works from and/or sell, transfer, and/or distribute such content and/or incorporate such content into any form, medium or technology throughout the world without compensation to you. Additionally,  Bookswagon may transfer or share any personal information that you submit with its third-party service providers, including but not limited to Bazaarvoice, Inc. in accordance with  Privacy Policy


    All content that you submit may be used at Bookswagon's sole discretion. Bookswagon reserves the right to change, condense, withhold publication, remove or delete any content on Bookswagon's website that Bookswagon deems, in its sole discretion, to violate the content guidelines or any other provision of these Terms of Use.  Bookswagon does not guarantee that you will have any recourse through Bookswagon to edit or delete any content you have submitted. Ratings and written comments are generally posted within two to four business days. However, Bookswagon reserves the right to remove or to refuse to post any submission to the extent authorized by law. You acknowledge that you, not Bookswagon, are responsible for the contents of your submission. None of the content that you submit shall be subject to any obligation of confidence on the part of Bookswagon, its agents, subsidiaries, affiliates, partners or third party service providers (including but not limited to Bazaarvoice, Inc.)and their respective directors, officers and employees.

    Accept

    Fresh on the Shelf


    Inspired by your browsing history


    Your review has been submitted!

    You've already reviewed this product!